Home > Insider Trading > Filing (0000929638-23-002058)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1822691	Greenlight Biosciences Holdings Pbc	GRNA	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1583977	Cormorant Asset Management, Lp	200 Clarendon Street 52Nd Floor Boston MA 02116	No	No	No	No
1599214	Bihua Chen	C/O Cormorant Asset Management, Lp 200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	No	No
1618442	Cormorant Global Healthcare Master Fund, Lp	200 Clarendon Street 52Nd Floor Boston MA 02116	No	No	No	No
1747677	Cormorant Private Healthcare Fund Ii, Lp	200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-07-20	9,188,659	$0.00	0	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes

Footnotes

Pursuant to the terms of previously disclosed Contribution and Exchange Agreements, the shares reported herein were contributed to SW ParentCo, Inc. ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.001 per share, of Parent.
Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP II, LLC ("GP II") serve as General Partner of the Master Fund and Fund II, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP II. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Represents (i) 4,751,020 shares of Common Stock that had been beneficially owned by the Master Fund and (ii) 4,437,639 shares of Common Stock that had been beneficially owned by Fund II.